Hyperuricemia and renal risk

High Blood Pressure and Cardiovascular Prevention

Volumn 21, Issue 3, 2014, Pages 189-194

  Viazzi, Francesca ^a   Leoncini, Giovanna ^a   Ratto, Elena ^a   Pontremoli, Roberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Cardio renal risk; Chronic kidney disease; Hypertension; Uric acid

Indexed keywords

ALLOPURINOL; URATE;

BLOOD PRESSURE REGULATION; CARDIORENAL SYNDROME; CHRONIC KIDNEY DISEASE; HYPERURICEMIA; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TREATMENT INDICATION; URIC ACID BLOOD LEVEL; CARDIOVASCULAR DISEASES; COMPLICATION; HUMAN; HYPERTENSION; RENAL INSUFFICIENCY, CHRONIC;

CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; HYPERURICEMIA; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84906669477     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/s40292-014-0042-7     Document Type: Review

References (55)

1. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;21(116):894-900. (Pubitemid 47300913)
2. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811-21 (Review).
3. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ. Uric acid, hominoid evolution and the pathogenesis salt-sensitivity. Hypertension. 2002;40:355-60. (Pubitemid 35006723)
4. Sanchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaria J, Nakagawa T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol. 2002;283:F1105-10. (Pubitemid 35192478)
5. Kanellis J, Watanabe S, Li JH, Kang D-H, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41:1287-93. (Pubitemid 36706079)
6. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2:275-81. (Pubitemid 128373654)
7. Mahomed FA. On chronic Bright's disease, and its essential symptoms. Lancet. 1879;1:399-401.
8. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63:102-10.
9. Mazzali M, Kanbay M, Segal MS, Shafiu M, Jalal D, Feig DI, Johnson RJ. Uric acid and hypertension: cause or effect? Curr Rheumatol Rep. 2010;12:108-17 (Review).
10. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300:924-32.
11. Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60:1148-56.
12. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442-7. (Pubitemid 46656248)
13. Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol. 2005;1:80-6.
14. Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008;57:845-52. (Pubitemid 351697915)
15. Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid: a facet of hyperinsulinaemia. Diabetologia. 1987;30:713-8. (Pubitemid 17155777)
16. Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: the Osaka Health Survey. J Hypertens. 2001;19:1209-15. (Pubitemid 32595276)
17. Nan H, Dong Y, Gao W, Tuomilehto J, Qiao Q. Diabetes associated with a low serum uric acid level in a general Chinese population. Diabetes Res Clin Pract. 2007;76:68-74. (Pubitemid 46240355)
18. Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, Saito A, Sone H. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32:1737-42.
19. Bhole V, Choi JW, Kim SW, de Vera M, Choi H. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med. 2010;123:957-61.
20. Wiik BP, Larstorp AC, Høieggen A, Kjeldsen SE, Olsen MH, Ibsen H, Lindholm L, Dahlöf B, Devereux RB, Okin PM, Wachtell K. Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Am J Hypertens. 2010;23:845-51.
21. Viazzi F, Leoncini G, Vercelli M, Deferrari G, Pontremoli R. Serum uric acid levels predict new-onset type 2 diabetes in hospitalized patients with primary hypertension: the MAGIC study. Diabetes Care. 2011;34:126-8.
22. Sánchez-Lozada LG, Tapia E, Bautista-García P, Soto V, Avila-Casado C, Vega-Campos IP, Nakagawa T, Zhao L, Franco M, Johnson RJ. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2008;294:F710-8.
23. Johnson RJ, Perez-Pozo SE, Sautin YY, Manitius J, Sanchez-Lozada LG, Feig DI, Shafiu M, Segal M, Glassock RJ, Shimada M, Roncal C, Nakagawa T. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev. 2009;30:96-116.
24. Curhan GC, Forman JP. Sugar-sweetened beverages and chronic disease. Kidney Int. 2010;77:569-70.
25. Viazzi F, Parodi D, Leoncini G, Parodi A, Falqui V, Ratto E, Vettoretti S, Bezante GP, Del Sette M, Deferrari G, Pontremoli R. Serum uric acid and target organ damage in primary hypertension. Hypertension. 2005;45:991-6. (Pubitemid 40628949)
26. Ishizaka N, Ishizaka Y, Toda E, Hashimoto H, Nagai R, Yamakado M. Higher serum uric acid is associated with increased arterial stiffness in Japanese individuals. Atherosclerosis. 2007;192:131-7. (Pubitemid 46602289)
27. Tanemoto M, Saitoh H, Satoh F, Satoh H, Abe T, Ito S. Predictors of undiagnosed renal artery stenosis among Japanese patients with risk factors of atherosclerosis. Hypertens Res. 2005;28:237-42. (Pubitemid 40812608)
28. Shankar A, Klein BE, Nieto FJ, Klein R. Association between serum uric acid level and peripheral arterial disease. Atherosclerosis. 2008;196:749-55. (Pubitemid 351146654)
29. Cuspidi C, Valerio C, Sala C, Meani S, Esposito A, Zanchetti A, Mancia G. Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. Am J Hypertens. 2007;20:678-85. (Pubitemid 46777264)
30. Mitsuhashi H, Yatsuya H, Matsushita K, Zhang H, Otsuka R, Muramatsu T, Takefuji S, Hotta Y, Kondo T, Murohara T, Toyoshima H, Tamakoshi K. Uric acid and left ventricular hypertrophy in Japanese men. Circ J. 2009;73:667-72.
31. Tarng DC, Lin HY, Shyong ML, Wang JS, Yang WC, Huang TP. Renal function in gout patients. Am J Nephrol. 1995;15:31-7.
32. Viazzi F, Leoncini G, Ratto E, Falqui V, Parodi A, Conti N, Derchi LE, Tomolillo C, Deferrari G, Pontremoli R. Mild hyperuricemia and subclinical renal damage in untreated primary hypertension. Am J Hypertens. 2007;20:1276-82. (Pubitemid 350151695)
33. Fukui M, Tanaka M, Shiraishi E, Harusato I, Hosoda H, Asano M, Kadono M, Hasegawa G, Yoshikawa T, Nakamura N. Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. Metabolism. 2008;57:625-9. (Pubitemid 351608223)
34. Tsioufis C, Chatzis D, Vezali E, Dimitriadis K, Antoniadis D, Zervoudaki A, Lalos S, Kallikazaros I, Stefanadis C, Toutouzas P. The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage. J Hum Hypertens. 2005;19:211-7. (Pubitemid 40360937)
35. Lee JE, Kim YG, Choi YH, Huh W, Kim DJ, Oh HY. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension. 2006;47:962-7. (Pubitemid 44297569)
36. Kohagura K, Kochi M, Miyagi T, Kinjyo T, Maehara Y, Nagahama K, Sakima A, Iseki K, Ohya Y. An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res. 2013;36:43-9.
37. Myllymäki J, Honkanen T, Syrjänen J, Helin H, Rantala I, Pasternack A, Mustonen J. Uric acid correlates with the severity of histopathological parameters in IgA nephropathy. Nephrol Dial Transplant. 2005;20:89-95. (Pubitemid 40207612)
38. Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2008;43:347-52.
39. Chen N, Wang W, Huang Y, Shen P, Pei D, Yu H, Shi H, Zhang Q, Xu J, Lv Y, Fan Q. Community-based study on CKD subjects and the associated risk factors. Nephrol Dial Transplant. 2009;24:2117-23.
40. Ishani A, Grandits GA, Grimm RH, Svendsen KH, Collins AJ, Prineas RJ, Neaton JD. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol. 2006;17:1444-52. (Pubitemid 43673426)
41. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19:2407-13.
42. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008;19:1204-11.
43. Jalal DI, Rivard CJ, Johnson RJ, Maahs DM, McFann K, Rewers M, Snell-Bergeon JK. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant. 2010;25:1865-9.
44. Oh CM, Park SK, Ryoo JH. Serum uric acid level is associated with the development of microalbuminuria in Korean men. Eur J Clin Invest. 2014;44:4-12.
45. Chang HY, Lee PH, Lei CC, Tung CW, Hsu YC, Huang TJ, Lu LC, Lin CL. Hyperuricemia is an independent risk factor for new onset micro-albuminuria in a middle-aged and elderly population: a prospective cohort study in Taiwan. PLoS ONE. 2013;8:e61450.
46. Akalin E, Ganeshan SV, Winston J, Muntner P. Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy. Transplantation. 2008;86:652-8.
47. Cicero AF, Rosticci M, Parini A, Baronio C, D'Addato S, Borghi C. Serum uric acid is inversely proportional to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: data from the Brisighella Heart Study. Intern Emerg Med. 2013.
48. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51-9. (Pubitemid 41828266)
49. Luk AJ, Levin GP, Moore EE, Zhou XH, Kestenbaum BR, Choi HK. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford). 2009;48:804-6.
50. Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I, Duranay M, Covic A, Johnson RJ. A randomized study of allopurinol on endothelial function and estimated glomerular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011;6:1887-94.
51. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388-93.
52. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508-16. (Pubitemid 44901524)
53. Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011;58:2-7.
54. Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, Sugihara S, Igawa O, Hosoya T, Ohtahara A, Shigamasa C, Yamamoto Y, Ninomiya H, Hisatome I. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens. 2008;21:1157-62.
55. Price KL, Sautin YY, Long DA, Zhang L, Miyazaki H, Mu W, Endou H, Johnson RJ. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol. 2006;17:1791-5. (Pubitemid 44036162)